Onglyza was first approved by the FDA for treatment of Type 2 diabetes in 2009. It quickly became popular because it regulated blood glucose without causing weight gain, a side effect of many Type 2 diabetes drugs. By 2015, Onglyza sales had reached $786 million and in April of 2016, the FDA issued an Onglyza Heart Failure Warning.
The New England Journal of Medicine published the results of a large study that tracked 16,000 patients over the course of two to three years, specifically analyzing the cardiovascular health of those patients. The study's findings demonstrated that those taking Onglyza or Kombiglyze XR hospitalized for a cardiac condition at a rate 27% higher than those in the study not receiving Onglyza or Kombiglyze XR. The study also determined that Onglyza and Kombiglyze XR users had elevated natriuretic peptide levels, which is an indicator of future heart disease and heart future. The FDA required that Onglyza and Kombiglyze XR now carry an additional product label warning for increased risk of heart failure.
Heart failure is when the heart is not able to pump the amount of blood required by the body. The first notice of this could be heart attack. Other symptoms of heart failure include shortness of breath, tiredness, fatigue, weakness, trouble breathing while lying down, heart palpitations, faster than usual heart rate, dizziness, faintness and lightheadedness, among other symptoms. Consult your physician immediately if you believe you have symptoms of heart failure.
Individuals and the family members of persons who have been diagnosed with heart failure, heart disease or suffered a heart attack may be entitled to real compensation through an Onglyza or Kombiglyze XR heart failure lawsuit. Our attorneys provide free Onglyza and Kombiglyze XR claim reviews, and will be happy to answer your questions and help you to understand your legal options. All Onglyza and Kombiglyze XR heart failure lawsuit services are provided on a contingency basis, meaning there are no legal fees unless we win compensation on your behalf.
Filing a lawsuit is the best means for individual consumers to hold pharmaceutical companies accountable for harmful products. By placing profit motives ahead of consumer safety, the makers of Onglyza and Kombiglyze XR have caused undue harm and loss to Americans and their families while lining their own pockets. Negligent and unscrupulous pharmaceutical companies can and should be held accountable for their actions, and injured consumers have a right to seek justice. Filing an Onglyza or Kombiglyze XR heart failure lawsuit enables consumers to hold the companies accountable for the safety of their products.
The Onder Law Firm has a national reputation for its work in family and consumer safety based on an ethic of hard work, reliable advice, and achieving results on behalf of our clients. We will work tirelessly to ensure each of our clients has trustworthy and excellent legal representation. Contact our attorneys to ensure you have an experienced advocate fighting on behalf of your family.
Whether you choose or firm to represent you or not, we are here to help. From offering free, no-obligation case reviews to providing contingency representation, we never charge a fee unless we win for you. Choosing an attorney is a significant decision and it is our goal to support you with information and expertise as you make your decision. Contact our firm today to speak with an experienced Onglyza or Kombiglyze XR heart failure attorney.
To speak with a lawyer handling Onglyza and Kombiglyze XR heart failure lawsuits, contact our firm today.
Scott G Williams MD, FACOG
Dr Williams is a board certified obstetrician/gynecologist who serves as chief medical consultant for Onder Law. During more than 20 years as a practicing ob/gyn in St Charles county, Dr Williams delivered thousands of babies, performed surgery on a daily basis, and was considered one of the top providers in his profession. He served as chief of ob/gyn at two of the three hospitals in St Charles county, and currently is the full time medical director of St Louis area obstetric hospitalist program.
In addition, Dr Williams has served as a long time consultant in medical and pharmaceutical litigation for Onder Law. With a background that includes scientific research as well as medical practice, Dr Williams is adept at interpreting pharmaceutical and medical device studies. His past analyses have included research on the harmful effects of contraceptive devices, talc/ ovarian cancer and the blood clotting effects of certain oral contraceptives.
Clients would not commonly meet with Dr Williams as he is not an attorney, but his expertise forms an important part of Onder Law's client strategies for medical and pharmaceutical products. Dr Williams is often a crucial "behind the scenes" part of formulating a winning approach for your case.
Scott G Williams, MD, FACOG, is a 1986 graduate of the University of Notre Dame. His MD was earned at the University of Missouri Columbia and he completed residency at the well regarded University of Florida-Gainesville Ob/Gyn program. Dr Williams and his wife (who is also a physician) live with two labrador retrievers; their son and daughter are at college.